Gupta Varsha, Shariff Mohammed, Bajwa Ravneet, Patel Ishan, Ayyad Hashem A, Levitt Michael J, Mencel Peter J, Hossain Mohammad A
Department of Medicine, Jersey Shore University Medical Center, Hackensack Meridian Health, Neptune, NJ, USA.
Department of Pathology, Jersey shore University Medical Center, Neptune, NJ, USA.
World J Oncol. 2019 Jun;10(3):153-156. doi: 10.14740/wjon1211. Epub 2019 Jun 29.
Acute promyelocytic leukemia (APL) is identified as the M3 subtype of acute myeloid leukemia (AML). APL is presently one of the most curable leukemias. We describe here a rare case of APL who presented as a relapsed disease after 1 year of chemotherapy for AML. The patient lacked t(15;17) at the initial presentation but was present later at the time of relapse. The patient attained a complete remission following treatment with all-trans retinoic acid (ATRA) and arsenic trioxide-based therapy. We discuss the possible mechanism behind secondary acquisition of promyelocytic leukemia/retinoic acid receptor alpha (PML-RARA) at relapse of AML. We also briefly discuss the clinical features, diagnosis and treatment of APL.
急性早幼粒细胞白血病（APL）被确定为急性髓系白血病（AML）的M3亚型。APL目前是最可治愈的白血病之一。我们在此描述一例罕见的APL病例，该患者在接受AML化疗1年后出现复发疾病。患者初诊时缺乏t(15;17)，但在复发时出现。患者接受全反式维甲酸（ATRA）和基于三氧化二砷的治疗后达到完全缓解。我们讨论了AML复发时继发性获得早幼粒细胞白血病/维甲酸受体α（PML-RARA）背后的可能机制。我们还简要讨论了APL的临床特征、诊断和治疗。
